Navigation Links
Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
Date:3/31/2008

Kingfisher's Revolutionary Device Designed to Improve Quality of Life for

Patients Suffering From Chronic Pain

ALBUQUERQUE, New Mexico, March 31 /PRNewswire/ -- Kingfisher Americas, a healthcare company focused on improving patient quality of life, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market KFH Energy in the United States. The patented, high-tech medical device is intended to improve upon quality of life for sufferers of chronic pain associated with post-polio syndrome, fibromyalgia, multiple sclerosis, and chronic fatigue syndrome.

"We are thrilled to introduce KFH Energy to physicians, specialists, and patients throughout the United States," said Dr. Henk Snyman, CEO and co-founder of Kingfisher Healthcare, the parent company of Kingfisher Americas. "Our clinical research on post-polio patients yielded dramatic improvements, and we are eager to address the strong population of chronic pain patients in the U.S. With the proven success of KFH Energy, we anticipate that this technology will be the first in a suite of natural energy devices for a variety of treatments."

KFH Energy utilizes a unique form of micro current electrotherapy called Bio-Electric Stimulation Therapy (BEST), which is designed to enhance the body's physiological processes. Intended for home use, KFH Energy encapsulates this novel technology in a hand-held device. Its sleek and modern design elements, including the patented touch-screen panel, make the device both convenient and easy to use. KFH Energy received CE mark in Europe in September 2007.

"There is a growing demand among individuals with chronic pain for alternative treatments to improve their condition," said Herb Whitaker, CEO of Kingfisher Americas. "We are excited to have this device available in the States and are committed to improving the lives of those who have been sidelined as a result of symptoms."

For more information about KFH Energy and its availability in the U.S., please visit http://www.kfamericas.com or http://www.kfhealth.com.

About Kingfisher Americas

Kingfisher Americas, a subsidiary of the Belgium-based Kingfisher Healthcare, is the first company to use safe, non-invasive energy to treat patients suffering from chronic conditions. It utilizes a technology platform called BEST (Bio-Electric Stimulation Therapy) from which unique products are developed by Kingfisher Healthcare. Headquartered in Albuquerque, New Mexico, Kingfisher Americas focuses on establishing relationships with patients, patient support groups, and medical experts to improve the quality of life of fibromyalgia, post polio, and chronic fatigue syndrome patients. For more information, please visit http://www.kfamericas.com.


'/>"/>
SOURCE Kingfisher Americas
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
2. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
3. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
4. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
5. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
6. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
7. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
10. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
11. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... PORTLAND, Oregon and PUNE, India ... According to a new report published by Allied Market ... Global Opportunity Analysis and Industry Forecast, 2014-2022," the ... million by 2022, from $5,768 million in 2015, growing ... The chemical & gas sterilization segment dominated the market ...
(Date:1/16/2017)... Bill is an internationally experienced medical device industry executive ... with global medical device companies, including Smith & Nephew, Angiodynamics, Orthovita ... products and building successful businesses in the sector and has worked ... and North America . ... Educated at the University of Edinburgh (Dental ...
(Date:1/16/2017)... 2017 CBDRx, the world,s premiere nutraceutical hemp ... rich hemp extract to Veteran,s groups across the country. ... hemp extract to Veteran,s groups across the United States.  ... in the world and through their passion, CBDRx honors ... phyto-nutrient rich hemp extract available. ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... ... San Francisco dentist, Dr. Ben Amini , the founder at CitiDent, ... capable of taking digital impressions of teeth and gums. Conventional bite impressions have lagged ... , in terms of speed, efficiency and patient comfort. Increasingly, digital impressions are being ...
(Date:1/16/2017)... ... ... NexTec Group has been selected as a member of the Bob Scott’s ... the field of midmarket financial software. , Members of the VAR Stars were selected ... based on revenue and those firms chosen represent a wide range of size and ...
(Date:1/15/2017)... , ... January 15, 2017 , ... ... Community Outreach is a program that strives to better communities around the world ... locations’ community. It also provides the opportunity for team members to become involved ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation ... achieved accreditation for its specialty care services. Albertsons Companies is the largest ... care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication ...
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco ... eight Bay Area counties for 2017. Almost 1,000 nominations were submitted and a ... award process. Results were announced the magazine’s January 2017 issue . , ...
Breaking Medicine News(10 mins):